← All trials
NCT05826574
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2023
- Primary completion
- Jul 16, 2023
- Completion date
- Jul 16, 2023
- First posted
- Apr 24, 2023
- Last posted
- Aug 21, 2023
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Insmed, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.